Descenso del PSA tras la cirugía de la HBP: estudio comparativo entre Resección transuretral de la próstata, Enucleación prostática con láser de Holmium y Adenomectomía retropúbica

INTRODUCCIÓ: Existeix una correlació entre els grams de pròstata ressecada per HBP i el descens de PSA. OBJECTIUS: Comparar el descens de PSA després de: RTUp, HoLEP i Adenomectomia retropúbica. MATERIAL I MÈTODES: 146 pacients intervinguts d'HBP: 50 AR, 50 HoLEP, 46 RTUp. Comparem el percentatge de reducció de PSA després dels tres procediments mitjançant ANOVA (p &0,05). RESULTATS: el percentatge de disminució de PSA és major després de la retropúbica (82,83%), seguit de l’HoLEP (68,45%) i de la RTUp (39,74%). CONCLUSIONS: No existeixen diferències estadísticament significatives en el descens de PSA entre l'AR i el HoLEP, però sí entre aquests dos i la RTUp.

La Baixa morbiditat perioperatòria de la prostatectomia radical laparoscòpica justifica efectuar-la en pacients majors de 70 anys

Donat l’increment en l’esperança de vida, valorem el tractament radical del càncer de pròstata en pacients & 70 anys. L’objectiu és analitzar la incidència, severitat i maneig de la morbiditat perioperatòria de la prostatectomia radical (PR) en funció de la tècnica quirúrgica. De 500 PR revisem, retrospectivament, 70 pacients & 70 anys (40 Retropúbiques i 30 Laparoscòpiques). S’empra la classificació de Clavien modificada per analitzar les complicacions. La proporció de complicacions és en PRR 57,5% i en PRL 33%. Les complicacions en la PRL són de menor gravetat. Els beneficis atribuïts a la laparoscòpia es mantenen en pacients d’edat avançada.

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer

Background: As the long-term efficacy of stereotactic body radiation therapy (SBRT) becomes established and other prostate cancer treatment approaches are refined and improved, examination of quality of life (QOL) following prostate cancer treatment is critical in driving both patient and clinical treatment decisions. We present the first study to compare QOL after SBRT and radical prostatectomy, with QOL assessed at approximately the same times pre- and post-treatment and using the same validated QOL instrument. Methods: Patients with clinically localized prostate cancer were treated with either radical prostatectomy (n = 123 Spanish patients) or SBRT (n = 216 American patients). QOL was assessed using the Expanded Prostate Cancer Index Composite (EPIC) grouped into urinary, sexual, and bowel domains. For comparison purposes, SBRT EPIC data at baseline, 3 weeks, 5, 11, 24, and 36 months were compared to surgery data at baseline, 1, 6, 12, 24,and 36 months. Differences in patient characteristics between the two groups were assessed using Chi-squared tests for categorical variables and t-tests for continuous variables. Generalized estimating equation (GEE) models were constructed for each EPIC scale to account for correlation among repeated measures and used to assess the effect of treatment on QOL. Results: The largest differences in QOL occurred in the first 16 months after treatment, with larger declines following surgery in urinary and sexual QOL as compared to SBRT, and a larger decline in bowel QOL following SBRT as compared to surgery. Long-term urinary and sexual QOL declines remained clinically significantly lower for surgery patients but not for SBRT patients. Conclusions: Overall, these results may have implications for patient and physician clinical decision making which are often influenced by QOL. These differences in sexual, urinary and bowel QOL should be closely considered in selecting the right treatment, especially in evaluating the value of non-invasive treatments, such as SBRT.

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer

Background: As the long-term efficacy of stereotactic body radiation therapy (SBRT) becomes established and other prostate cancer treatment approaches are refined and improved, examination of quality of life (QOL) following prostate cancer treatment is critical in driving both patient and clinical treatment decisions. We present the first study to compare QOL after SBRT and radical prostatectomy, with QOL assessed at approximately the same times pre- and post-treatment and using the same validated QOL instrument. Methods: Patients with clinically localized prostate cancer were treated with either radical prostatectomy (n = 123 Spanish patients) or SBRT (n = 216 American patients). QOL was assessed using the Expanded Prostate Cancer Index Composite (EPIC) grouped into urinary, sexual, and bowel domains. For comparison purposes, SBRT EPIC data at baseline, 3 weeks, 5, 11, 24, and 36 months were compared to surgery data at baseline, 1, 6, 12, 24,and 36 months. Differences in patient characteristics between the two groups were assessed using Chi-squared tests for categorical variables and t-tests for continuous variables. Generalized estimating equation (GEE) models were constructed for each EPIC scale to account for correlation among repeated measures and used to assess the effect of treatment on QOL. Results: The largest differences in QOL occurred in the first 1-6 months after treatment, with larger declines following surgery in urinary and sexual QOL as compared to SBRT, and a larger decline in bowel QOL following SBRT as compared to surgery. Long-term urinary and sexual QOL declines remained clinically significantly lower for surgery patients but not for SBRT patients. Conclusions: Overall, these results may have implications for patient and physician clinical decision making which are often influenced by QOL. These differences in sexual, urinary and bowel QOL should be closely considered in selecting the right treatment, especially in evaluating the value of non-invasive treatments, such as SBRT.